New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
13:45 EDTBAYRY, BAYRY, BAYRY, CELG, CELG, CELG, LLY, LLY, LLY, ONXX, ONXX, ONXX, REGN, REGN, REGN, SNY, SNY, SNYLeerink's biotech analyst hosts a luncheon meeting
Biotech Analyst Liang discusses the ongoing ASCO GI Cancer Symposium, physician impressions of the new Phase 3 data on CELG’s Abraxane and LLY’s Ramucirumab, as well as market dynamics for new agents in colorectal cancer such as Zaltrap and Stivarga at a Luncheon Meeting being held in San Francisco on January 25 at 2 pm.
News For BAYRY;CELG;LLY;ONXX;REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 31, 2015
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
08:14 EDTREGNRegeneron downgraded to Neutral from Buy at Chardan
Subscribe for More Information
07:45 EDTREGNRegeneron should be bought on any pullbacks, says RBC Capital
Subscribe for More Information
06:35 EDTSNY, REGNAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTSNY, REGNAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
08:01 EDTSNY, REGNAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
07:12 EDTCELGWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
19:14 EDTREGN, SNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
16:03 EDTCELGCelgene completes acquisition of Receptos
Subscribe for More Information
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
10:14 EDTBAYRYForward signs supplier agreement extension with Bayer Healthcare
Subscribe for More Information
08:21 EDTREGNRegeneron has multiple catalysts, says Leerink
Subscribe for More Information
07:31 EDTCELGCelgene announces expiration of tender offer for Receptos shares
Subscribe for More Information
August 24, 2015
18:55 EDTCELGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTCELGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
13:36 EDTCELGBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
07:23 EDTREGNRegeneron should be bought on pullbacks, says RBC Capital
Subscribe for More Information
August 23, 2015
12:35 EDTREGN, CELGBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use